Does it Matter What Time of Day You See Your Oncologist?

A new study out of Boston demonstrates a tendency among physicians to make different, less rigorous clinical decisions in the later hours of the day compared to the early hours.

The team begins this study by making the following statement:

Clinicians make many patient care decisions each day. The cumulative cognitive demand of these decisions may erode clinicians’ abilities to resist making potentially inappropriate choices. Psychologists, who refer to the erosion of self-control after making repeated decisions as decision fatigue have found evidence that it affects nonmedical professionals. For example, as court sessions wear on, judges are more likely to deny parole, the “easier” or “safer” option.

With that inauspicious beginning, Jeffrey A. Linder of Brigham and Women's Hospital in Boston and colleagues launch into a study in which they analyzed the diagnosis of acute respiratory infections in nearly 22,000 cases over a time frame of 18 months.

What they found was that the likelihood among these clinicians to prescribe antibiotics went up as the day wore on—whether or not antibiotics were actually indicated by the patient's symptoms. Compared to the first hour of the workday:

  • In the second hour, the probability of an antibiotics prescription rose by 1 percent.
  • In the third hour, it shot up to 14 percent.
  • In the fourth hour, it went all the way up to 26 percent.

Linder told the New York Times that doctors "may be fatigued and make worse decisions toward the end of our clinic sessions."

While the study itself involved primary care physicians, nurse practitioners, and even some physician trainees, it doesn't take a stretch of the imagination or a reinterpretation of the results to believe that decision fatigue has just as much likelihood to affect the decisions made by oncologists, especially when one considers how much career burn-out can be found among this group of doctors.

"The radical notion here is that doctors are people too," added Linder, a comment I read as a sad attempt to justify laziness.

Does this mean that you should always see your oncologist in the morning hours? No, it doesn't necessarily mean that, especially since that's simply not possible for many patients. But it should serve as a reminder that your appointment time with your doctor is far more important to you than it is to him or her, and that it is ultimately up to you the patient to take an active role in getting the most out of your physician's care.

Sources:
Time of Day and the Decision to Prescribe Antibiotics
NYT: Doctors and Decision Fatigue

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap